Results 21 to 30 of about 191 (111)

Shen Qi Wan‐Containing Serum Alleviates Renal Interstitial Fibrosis via Restraining Notch1‐Mediated Epithelial‐Mesenchymal Transition

Evidence-Based Complementary and Alternative Medicine, Volume 2023, Issue 1, 2023., 2023
Objective. Shen Qi Wan (SQW) is the most classic prescription for the clinical therapy of chronic kidney disease in China. Nevertheless, the function of SQW in renal interstitial fibrosis (RIF) has not been clearly clarified. Our purpose was to explore the protective function of SQW on RIF. Methods. After intervention with SQW‐containing serum alone at
Hongshu Chen, Xiaojie Zhou, Yuanxiao Yang, Yaorong Feng, Guang Chen   +4 more
wiley   +1 more source

Secondary analysis of Huangkui capsule in the treatment of IgAN

, 2023
Abstract Background: IgA nephropathy is the most common primary glomerular disease and an important cause of chronic kidney disease. Previous clinical studies have confirmed that Huangkui capsule could reduce urine protein of IgA nephropathy by 100 mg/d losartan potassium.
Zenghui Xing, Bing Han, Yixuan Zhang, Sichen Li, Chao Liu, Yiqin Wang, Hongli Lin, Zhaohui Ni, Yongli Zhan, Guangyan Cai, Qinkai Chen, Xiaoqin Wang, Peiqing Zhang, Peng Li, Niansong Wang, Lining Miao, Yong Wang, Xiangmei Chen, Xuefeng Sun   +18 more
openaire   +1 more source

The Effectiveness and Safety of Abelmoschus manihot in Treating IgA Nephropathy: A Systematic Review and Meta‐Analysis

Evidence-Based Complementary and Alternative Medicine, Volume 2022, Issue 1, 2022., 2022
Introduction. IgA nephropathy (IgAN) is a common issue. In China, Abelmoschus manihot (AM) is widely used in the treatment of IgAN. However, their combined effectiveness and safety for this purpose have not yet been explored. AM is an effective medicine for treating IgAN. This meta‐analysis aimed to evaluate the effectiveness of AM for IgAN.
Qi Jia, Jing Guo, Yuzi Cai, Weijun Huang, Zebing Zhu, Chenhui Xia, Keting Guo, Hongcai Shang, Yuning Liu, Weijing Liu, George B. Lenon   +10 more
wiley   +1 more source

What was new at the 2023 American Diabetes Association meeting?

, 2023
Journal of Diabetes, Volume 15, Issue 8, Page 636-639, August 2023.
Zachary Bloomgarden
wiley   +1 more source

Huangkui Capsule Ameliorates Renal Fibrosis in a Unilateral Ureteral Obstruction Mouse Model Through TRPC6 Dependent Signaling Pathways [PDF]

Frontiers in Pharmacology, 2020
Renal fibrosis is the final common pathological manifestation of almost all progressive chronic kidney diseases (CKD). Transient receptor potential canonical (TRPC) channels, especially TRPC3/6, were proposed to be essential therapeutic targets for kidney injury.
Li-fei Gu, Hai-tao Ge, Lei Zhao, Yu-jing Wang, Fan Zhang, Hai-tao Tang, Zheng-yu Cao, Bo-yang Yu, Cheng-zhi Chai   +8 more
openaire   +3 more sources

Hyperoside Alleviates High Glucose‐Induced Proliferation of Mesangial Cells through the Inhibition of the ERK/CREB/miRNA‐34a Signaling Pathway

International Journal of Endocrinology, Volume 2020, Issue 1, 2020., 2020
Purpose. Hyperoside, a flavonoid isolated from conventional medicinal herbs, has been demonstrated to exert a significant protective effect in diabetic nephropathy. This study aimed to determine the underlying mechanisms, by which hyperoside inhibits high glucose‐(HG‐) induced proliferation in mouse renal mesangial cells. Methods.
Le Zhang, Qian Dai, Lanlan Hu, Hua Yu, Jing Qiu, Jiyin Zhou, Min Long, Shiwen Zhou, Kebin Zhang, Tatsuya Kin   +9 more
wiley   +1 more source

Mechanisms of Herbal Nephroprotection in diabetes mellitus

Journal of Diabetes Research, Volume 2020, Issue 1, 2020., 2020
Diabetic nephropathy (DN) is a leading cause of kidney morbidity. Despite the multilayered complexity of the mechanisms involved in the pathogenesis of DN, the conventional treatment is limited to just a few drug classes fraught with the risk of adverse events, including the progression of renal dysfunction. Phytoceuticals offer a promising alternative
Dorin Dragoș, Maria Mirabela Manea, Delia Timofte, Dorin Ionescu, Eric Hajduch   +4 more
wiley   +1 more source

Clinical efficacy of Huangkui capsules in the treatment of targeted drug-related proteinuria in patients with hepatocellular carcinoma

Zhongguo Linchuang Yixue
ObjectiveTo investigate the therapeutic effect of Huangkui capsules on targeted drug-related proteinuria in patients with hepatocellular carcinoma (HCC).
Miao Li, Jia Yuan, Chu Liu, Maopei Chen, Xin Xu, Ningling Ge, Yi Chen, Lan Zhang, Rongxin Chen, Yan Wang   +9 more
doaj   +1 more source

Prospective clinical study of Kunkui Baoshen Formula in the treatment of high or extremely high-risk diabetic kidney disease

Zhongguo linchuang yanjiu
Objective To compare the clinical efficacy of Kunkui Baoshen Formula and Huangkui Capsules in patients with high or extremely high-risk diabetic kidney disease (DKD), and to explore the safety of their clinical application.
TAN Ying*, ZHOU Xiqiao, HUANG Liji, ZHANG Qiling, ZHOU Peipei, SONG Siyuan, ZHA Min, YAN Qianhua, YU Jiangyi
doaj   +1 more source

The Efficacy and Mechanism of Chinese Herbal Medicine on Diabetic Kidney Disease

Journal of Diabetes Research, Volume 2019, Issue 1, 2019., 2019
Diabetic kidney disease (DKD) is the most common microvascular complication of diabetes and is one of the main causes of end‐stage renal disease (ESRD) in many countries. The pathological features of DKD are the hypertrophy of mesangial cells, apoptosis of podocytes, glomerular basement membrane (GBM) thickening, accumulation of extracellular matrix ...
Zhenzhen Lu, Yifei Zhong, Wangyi Liu, Ling Xiang, Yueyi Deng, Akira Sugawara   +5 more
wiley   +1 more source